SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study
Posted on 2022-06-28 - 09:13
Abstract Background People experiencing homelessness (PEH) and associated shelter workers may be at higher risk of infection with “Severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The aim of this study was to determine the prevalence of SARS-CoV-2 among PEH and shelter workers in Denmark. Design and methods In November 2020, we conducted a nationwide cross-sectional seroprevalence study among PEH and shelter workers at 21 recruitment sites in Denmark. The assessment included a point-of-care test for antibodies against SARS-CoV-2, followed by a questionnaire. The seroprevalence was compared to that of geographically matched blood donors considered as a proxy for the background population, tested using a total Ig ELISA assay. Results We included 827 participants in the study, of whom 819 provided their SARS-CoV-2 antibody results. Of those, 628 were PEH (median age 50.8 (IQR 40.9–59.1) years, 35.5% female) and 191 were shelter workers (median age 46.6 (IQR 36.1–55.0) years and 74.5% female). The overall seroprevalence was 6.7% and was similar among PEH and shelter workers (6.8% vs 6.3%, p = 0.87); and 12.2% among all participants who engaged in sex work. The overall participant seroprevalence was significantly higher than that of the background population (2.9%, p < 0.001). When combining all participants who reported sex work or were recruited at designated safe havens, we found a significantly increased risk of seropositivity compared to other participants (OR 2.23, 95%CI 1.06–4.43, p = 0.02). Seropositive and seronegative participants reported a similar presence of at least one SARS-CoV-2 associated symptom (49% and 54%, respectively). Interpretations The prevalence of SARS-CoV-2 antibodies was more than twice as high among PEH and associated shelter workers, compared to the background population. These results could be taken into consideration when deciding in which phase PEH are eligible for a vaccine, as part of the Danish national SARS-CoV-2 vaccination program rollout. Funding TrygFonden and HelseFonden.
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Eriksen, Alexandra R Röthlin; Fogh, Kamille; Hasselbalch, Rasmus B.; Bundgaard, Henning; Nielsen, Susanne D.; Jørgensen, Charlotte S.; et al. (2022). SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study. figshare. Collection. https://doi.org/10.6084/m9.figshare.c.6067880.v1
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (35)
AE
Alexandra R Röthlin Eriksen
KF
Kamille Fogh
RH
Rasmus B. Hasselbalch
HB
Henning Bundgaard
SN
Susanne D. Nielsen
CJ
Charlotte S. Jørgensen
BS
Bibi F. S. S. Scharff
CE
Christian Erikstrup
SS
Susanne G. Sækmose
DH
Dorte K. Holm
BA
Bitten Aagaard
JK
Jonas H. Kristensen
CB
Cecilie A. Bødker
JN
Jakob B. Norsk
PN
Pernille B. Nielsen
LØ
Lars Østergaard
SE
Svend Ellermann-Eriksen
BA
Berit Andersen
HN
Henrik Nielsen
IJ
Isik S. Johansen
KEYWORDS
median age 50median age 46designated safe havens9 – 5921 recruitment sites06 – 4seronegative participants reportedleast one sarsdanish national sars9 %, p3 %, p2 associated symptomsignificantly increased riskreported sex workassociated shelter workers1 – 55high among pehincluded 827 participantsoverall participant seroprevalencesimilar among peh2 antibody results2 among pehshelter workerssex worksimilar presencesignificantly higheroverall seroprevalencehigher riskassessment includedphase peh2 ).tested usingresults couldnovember 2020nationwide crossiqr 40iqr 36funding trygfondenci 1care testbackground population87 );819 provided02 ).001 ).